Amsterdam, The Netherlands (ots/PRNewswire) - Norgine B.V.
("Norgine"), today announced the establishment of a wholly-owned
subsidiary, Norgine Healthcare B.V. ("Norgine Healthcare"), which
will be dedicated to consumer healthcare.
To view the Multimedia News Release, please click:
Norgine Healthcare will drive Norgine's consumer healthcare business,
including the MOVICOL® franchise, a portfolio of laxatives for the
treatment of chronic constipation that currently helps approximately
8 million patients a year around the world. 
The new subsidiary will be headed by Eric Alsac, who is currently
General Manager of Norgine The Netherlands.
Norgine Healthcare B.V. will assume immediate control of Norgine's
existing consumer healthcare franchises. It will also build a broader
consumer healthcare business with the acquisition of new,
transformative brands that will help to strengthen its offering as a
leading European pharmaceutical company and benefit more patients.
Norgine B.V. will continue to focus on speciality pharmaceutical
brands to address highly targeted, unmet medical needs.
Peter Stein, Chief Executive Officer of Norgine said, "The
establishment of Norgine Healthcare B.V. will help us to increase the
value of Norgine's current portfolio of healthcare consumer brands
and strengthen our commitment to bringing new transformative products
to patients across the world."
Christopher Bath, Chief Operating Officer of Norgine said, "As well
as meeting the needs of patients tomorrow through the development of
innovative products, we are committed to maximising the potential of
our current portfolio of brands that already help millions of
patients around the world."
Eric Alsac, General Manager of Norgine Healthcare B.V. said, "This is
a really exciting opportunity for us to ensure that our consumer
focused brands receive the attention that they deserve so that we can
better serve the needs of our patients."
Norgine Healthcare B.V. will be fully operational from 1st December
2020 and will be based in Amsterdam, The Netherlands.
Norgine is a leading European specialist pharmaceutical company that
has been bringing transformative medicines to patients for over a
century. Our commitment to transforming people's lives drives
everything we do and our European experience, fully integrated
infrastructure and exceptional partnership approach enables us to
quickly apply creative solutions to bring life-changing medicines to
patients that they may not otherwise be able to access. Norgine is
proud to have helped 22 million patients around the world in 2019 and
generated more than EUR419 million in net product sales, a growth of
6% over 2018.
Norgine has a direct presence in 12 European countries, as well as
Australia and New Zealand. We also have a strong global network of
partnerships in non-Norgine markets. We are a flexible and fully
integrated pharmaceutical business, with manufacturing (Hengoed,
Wales and Dreux, France), third party supply networks and significant
product development capabilities, in addition to our sales and
marketing infrastructure. This enables us to acquire, develop and
commercialise specialist and innovative products that make a real
difference to the lives of patients around the world.
In 2012, Norgine established Norgine Ventures, a complementary
business which supports innovative healthcare companies through the
provision of debt-like financing in Europe and the US. For more
information, please visit www.norgineventures.com
MOVICOL® is a laxative, the first polyethylene glycol preparation,
indicated for the treatment of chronic constipation in adults,
adolescents, the elderly and children. MOVICOL® is also effective in
resolving faecal impaction, defined as refractory constipation with
faecal loading of the rectum and/or colon. 
MOVICOL® was first launched in 1995 and over the past 25 years the
MOVICOL® franchise has continued to evolve to meet patients' needs.
MOVICOL® is currently marketed in Europe by Norgine B.V. and was also
made available in Japan by EA Pharma Co., Ltd in 2018.
Follow us @norgine
 MOVICOL® Summary of Product Characteristics. Available at
et,+powder+for+oral+solution/#gref Accessed November 2020
 MOVICOL® Paediatric Plain, Summary of Product Characteristics.
Available at https://www.medicines.org.uk/emc/product/52/smpc#gref
Accessed November 2020
Video - https://mma.prnewswire.com/media/1345522/PeterStein.mp4
Logo - https://mma.prnewswire.com/media/597589/Norgine_Logo.jpg
Digital press kit: http://www.ots.at/pressemappe/PR80824/aom
Aktien auf dem Radar:FACC, Österreichische Post, Zumtobel, Frequentis, Agrana, AT&S, Warimpex, Bawag, Flughafen Wien, voestalpine, DO&CO, EVN, Mayr-Melnhof, Wienerberger, Andritz, Verbund, Hutter & Schrantz, Palfinger, Heid AG, Semperit, SW Umwelttechnik, Oberbank AG Stamm, Linz Textil Holding, Rath AG.
Sicherheit, Nachhaltigkeit und Kundenorientierung sind im Bankgeschäft Grundvoraussetzungen für den geschäftlichen Erfolg. Die HYPO Oberösterreich ist sicherer Partner für mehr als 100.000 Kunden und Kundinnen. Die Bank steht zu 50,57 Prozent im Eigentum des Landes Oberösterreich. 48,59 Prozent der Aktien hält die HYPO Holding GmbH. An der HYPO Holding GmbH sind die Raiffeisenlandesbank Oberösterreich AG, die Oberösterreichische Versicherung AG sowie die Generali AG beteiligt.
>> Besuchen Sie 61 weitere Partner auf boerse-social.com/partner
Mehr aktuelle OTS-Meldungen HIER